Dr. Shengbin Shi 时圣彬
Chief Physician
Medical Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of digestive tract tumors, including esophageal, gastric, colorectal cancer, gastrointestinal stromal tumors, and neuroendocrine tumors. Specializes in treating peritoneal metastasis from colorectal and gastric cancer.
Dr. Shi holds a medical doctorate from Peking Union Medical College. Serves as Chief Physician and Deputy Director of the Second Ward of Gastroenterology and the Clinical Research Department at Shandong Cancer Hospital.
Professional roles
- Vice Chair, Youth Committee of Cancer Rehabilitation Branch, Shandong Anti-Cancer Association
- Member, Multidisciplinary Branch of Digestive Tract Tumors, China Health Care Promotion Association
- Vice Chair, Tumor Rehabilitation Branch, Shandong Rehabilitation Medical Association
- Standing Committee Member, Chemotherapy Physician Branch, Shandong Medical Doctor Association
Name order: in Chinese the family name comes first (Shi Shengbin). Papers usually list the name as Shengbin Shi or Shi S.
Selected publications
13 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Exp Clin Cancer Res, 2025 (senior author): Targeting NOTCH1-KEAP1 axis retards chronic liver injury and liver cancer progression via regulating stabilization of NRF2. PubMed 40781716
- J Hepatol, 2025 (senior author): Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression. PubMed 39260704
- Cancer Immunol Immunother, 2023 (senior author): Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma. PubMed 37665374
- Front Oncol, 2022 (senior author): The full management from first-line to third-line treatments in patients with Her-2-negative advanced gastric cancer. PubMed 36457494
- Mol Immunol, 2021 (first author): Serum-derived exosomes function as tumor antigens in patients with advanced hepatocellular carcinoma. PubMed 33819783
- Transl Oncol, 2018 (first author): Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model. PubMed 29413757
- Transl Res, 2016 (first author): MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. PubMed 26687391
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion